ホームMCPワークベンチSkills
ホームワークベンチ通知マイページ
llms.txt · MCPガイドプライバシーポリシー · 利用規約 · サポートv1.8.0
  1. ホーム
  2. /化合物

Acetylsalicylate

HCID 3434975
ノートを作成反応を作成見積依頼を出す
印刷プレビュー
基本情報概要名称と識別子物性安全と法規制化学と産業関連反応化合物ノート
部分構造検索類似構造を探す

基本情報

CAS
5054-56-8
標準SMILES
CC(=O)Oc1ccccc1C(=O)[O-]
InChIKey
BSYNRYMUTXBXSQ-UHFFFAOYSA-M
分子式
C9H7O4-
平均分子量
179.15 g/mol
単同位体質量
179.0344337

概要

Acetylsalicylate is a benzoate that is the conjugate base of acetylsalicylic acid, arising from deprotonation of the carboxy group. It is functionally related to a salicylate. It is a conjugate base of an acetylsalicylic acid.

名称と識別子

優先名称
Acetylsalicylate
IUPAC
2-acetyloxybenzoate

名称と別名

AcetylsalicylateCHEBI:13719RefChem:5525112-acetyloxybenzoate2-(acetyloxy)benzoateo-AcetoxybenzoateBSYNRYMUTXBXSQ-UHFFFAOYSA-MDTXSID8012874655054-56-8Benzoic acid, 2-(acetyloxy)-, ion(1-)Q27108970

データベース識別子

CAS
5054-56-8
PubChem CID
3434975
DTXSID
DTXSID801287465
ChEBI
CHEBI:13719
Nikkaji
J730.352A

物性

構造計算による物性

XLogP
1.8
極性表面積
66.4 Ų
水素結合供与体数
0
水素結合受容体数
4
回転可能結合数
2
重原子数
13
形式電荷
-1
複雑度
206

実験および物理化学的性質

Human DrugsBreast Feeding; Lactation; Milk, Human; Analgesic Agents; Anti-Inflammatory Agents, Non-Steroidal; Platelet Aggregation Inhibitors

安全と法規制

安全情報は参考情報です。供給元の安全データシート(SDS)、適用法令、専門家による評価に代わるものではありません。

毒性情報

Health Effects · 1 件

Might increase the risk of gastrointestinal bleeding; large doses of salicylate, a metabolite of aspirin, have been proposed to cause tinnitus; Reye's syndrome, a severe illness characterized by acute encephalopathy and fatty liver, can occur when children or adolescents are given aspirin for a fever or other illnesses or infections. [Wikipedia]

Exposure RoutesAbsorption is generally rapid and complete following oral administration but may vary according to specific salicylate used, dosage form, and other factors such as tablet dissolution rate and gastric or intraluminal pH.
Toxicity Summary · 1 件

The analgesic, antipyretic, and anti-inflammatory effects of acetylsalicylic acid are due to actions by both the acetyl and the salicylate portions of the intact molecule as well as by the active salicylate metabolite. Acetylsalicylic acid directly and irreversibly inhibits the activity of both types of cyclooxygenase (COX-1 and COX-2) to decrease the formation of precursors of prostaglandins and thromboxanes from arachidonic acid. This makes acetylsalicylic acid different from other NSAIDS (such as diclofenac and ibuprofen) which are reversible inhibitors. Salicylate may competitively inhibit prostaglandin formation. Acetylsalicylic acid's antirheumatic (nonsteroidal anti-inflammatory) actions are a result of its analgesic and anti-inflammatory mechanisms; the therapeutic effects are not due to pituitary-adrenal stimulation. The platelet aggregation-inhibiting effect of acetylsalicylic acid specifically involves the compound's ability to act as an acetyl donor to cyclooxygenase; the nonacetylated salicylates have no clinically significant effect on platelet aggregation. Irreversible acetylation renders cyclooxygenase inactive, thereby preventing the formation of the aggregating agent thromboxane A2 in platelets. Since platelets lack the ability to synthesize new proteins, the effects persist for the life of the exposed platelets (7-10 days). Acetylsalicylic acid may also inhibit production of the platelet aggregation inhibitor, prostacyclin (prostaglandin I2), by blood vessel endothelial cells; however, inhibition prostacyclin production is not permanent as endothelial cells can produce more cyclooxygenase to replace the non-functional enzyme.

化学と産業

薬理情報

Metabolism/Metabolites · 1 件

Acetylsalicylic acid is rapidly hydrolyzed primarily in the liver to salicylic acid, which is conjugated with glycine (forming salicyluric acid) and glucuronic acid and excreted largely in the urine. Half Life: The plasma half-life is approximately 15 minutes; that for salicylate lengthens as the dose increases: doses of 300 to 650 mg have a half-life of 3.1 to 3.2 hours; with doses of 1 gram, the half-life is increased to 5 hours and with 2 grams it is increased to about 9 hours.

用途と製造

Uses · 1 件

For use in the temporary relief of various forms of pain, inflammation associated with various conditions (including rheumatoid arthritis, juvenile rheumatoid arthritis, systemic lupus erythematosus, osteoarthritis, and ankylosing spondylitis), and is also used to reduce the risk of death and/or nonfatal myocardial infarction in patients with a previous infarction or unstable angina pectoris.

関連反応

3 件
反応記録を作成
HRID 208280 の反応式
HRID 208280生成物としてTraining data from https://doi.org/10.1039/C8SC04228D (6/10)
HRID 1288430 の反応式
HRID 1288430反応物としてuspto-grants-1976_10
HRID 2126675 の反応式
HRID 2126675生成物としてTraining data from https://doi.org/10.1039/C8SC04228D (4/10)

化合物ノート

読み込み中…

このページの内容基本情報概要名称と識別子物性安全と法規制化学と産業関連反応化合物ノート
その他の操作
ノートを作成反応を作成見積依頼を出す
Signs and Symptoms
Effects of overdose include: tinnitus, abdominal pain, hypokalemia, hypoglycemia, pyrexia, hyperventilation, dysrhythmia, hypotension, hallucination, renal failure, confusion, seizure, coma, and death.
Carcinogen ClassificationNo indication of carcinogenicity to humans (not listed by IARC).
Effects During Pregnancy and Lactation◉ Summary of Use during Lactation
Toxicity DataLD50: 250 mg/kg (Oral, Mouse) (A308) LD50: 1010 mg/kg (Oral, Rabbit) (A308) LD50: 200 mg/kg (Oral, Rat) (A308)